🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "huge turning point" in the effort against superbug strains of the bacteria, according to researchers.

A Worldwide Challenge

Gonorrhoea infections are escalating worldwide, with figures suggesting in excess of 82 million new cases per year. Especially elevated rates are seen in Africa and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune development in the reality of growing infection rates, increasing antimicrobial resistance and the extremely scarce therapeutic options at this time.”

Medical experts are particularly alarmed about the surge in drug-resistant strains. The World Health Organization has listed it as a "critical concern". Ongoing monitoring revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Gain Clearance

Zoliflodacin, also known as Nuzolvence, was cleared by the US FDA in mid-December for treating gonorrhoea. This STI can lead to serious health problems, including infertility. Scientists hope that focused deployment of this new drug will help delay the development of resistance.

Gepotidacin, developed by the pharmaceutical company GSK, gained clearance in concurrent days. This treatment, which is employed against UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a unique collaborative effort for drug creation. The non-profit organisation GARDP worked alongside the pharmaceutical company Innoviva to bring it to fruition.

“This approval represents a significant shift in the management of multidrug-resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Research Study Data and Global Access

Based on findings released by a major medical journal, the new drug successfully treated over nine in ten of uncomplicated infections. This establishes an comparable level with the typical regimen, which involves two antibiotics. The study involved hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the ability to make available and distribute the drug in numerous developing nations.

Doctors on the front lines have voiced optimism. Having a single-dose, oral treatment of this kind is seen as a "revolutionary step" for managing the epidemic. This is considered vital to lessen the impact of the disease for people and to prevent the spread of untreatable gonorrhoea around the world.